Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37 and keeps an Underweight rating on the shares. 2026 revenue and EPS guidance came in above consensus, but was driven by a higher than expected Eliquis guide, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
-
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
Disclaimer & DisclosureReport an Issue
-
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
-
Bristol Myers price target raised to $72 from $62 at Guggenheim
-
Bristol Myers price target raised to $60 from $55 at Wells Fargo
